Precision Biosciences Inc (DTIL) Stock Price & Analysis

Precision Biosciences Inc (DTIL) rose 1.33% to USD 6.86 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.

DTIL last closed at USD 6.77; the session ranged USD 6.69–7.24 on volume of 555,095 shares. Market capitalization is $177.00M, with a 52-week range of USD 3.53–8.82 (NCM). Source: Nexqual, June 10, 2026 at 00:44 UTC.

Key Statistics (as of June 10, 2026 at 00:44 UTC)

Technical Analysis (DTIL)

Nexqual's technical model rates DTIL "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.

Analyst Ratings (DTIL)

Wall Street analysts rate DTIL "Strong Buy" based on 5 analysts, with a mean price target of USD 29.6 (range USD 19–60), per Nexqual as of June 10, 2026 at 00:44 UTC.

Earnings (DTIL)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financials & Fundamentals (DTIL)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financial Health Score (DTIL)

Nexqual rates Precision Biosciences Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:44 UTC.

Ownership (DTIL)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Leadership (DTIL)

Precision Biosciences Inc is led by Michael Amoroso (age 47), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:44 UTC.

Major Backers & Investors (DTIL)

Notable institutional backers of Precision Biosciences Inc include Octagon Capital Advisors LP, Aberdeen Group plc, Empery Asset Management, LP, according to Nexqual as of June 10, 2026 at 00:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

From Precision Biosciences Inc's Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Recently, iECURE reached alignment with the FDA on the primary and key secondary efficacy endpoints, comparators and study size for the ongoing OTC-HOPE study which could support a Biologics License Application.
• We seek to protect our proprietary technology and processes, in part, by monitoring confidential disclosures and through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment or term of service.
• Furthermore, we rely upon a combination of patents and trade secret protection, as well as license and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product candidates.
• We also rely on trademarks, trade secrets, know-how, continuing technological innovation and confidential information, and the pursuit of licensing opportunities, to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

Partnerships

• In partnership with iECURE, Inc. ("iECURE"), an ARCUS-mediated targeted gene insertion approach, ECUR-506, is being evaluated as a potential curative treatment option for neonatal onset ornithine transcarbamylase ("OTC") deficiency.
• In connection with the iECURE DLA, we and iECURE entered into an equity issuance agreement (the "iECURE Equity Agreement"), pursuant to which iECURE issued us common stock in iECURE as additional consideration for the license to use our PCSK9-directed ARCUS nuclease.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.